Clinical Trials Logo

Non-Hodgkin Lymphoma (NHL) clinical trials

View clinical trials related to Non-Hodgkin Lymphoma (NHL).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02259348 Terminated - Clinical trials for Acute Myeloid Leukemia (AML)

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Start date: October 2014
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating younger patients with hematologic malignancies that have returned after or did not respond to treatment with a prior transplant. Giving chemotherapy and natural killer cells before a donor progenitor cell transplant may help stop the growth of cells in the bone marrow, including normal blood-forming cells (progenitor cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's cells. When the healthy progenitor cells from a related donor are infused into the patient they make red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Removing specific T cells from the donor cells before the transplant may prevent this.

NCT ID: NCT01220297 Terminated - Leukemia Clinical Trials

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Start date: August 2006
Phase: Phase 2
Study type: Interventional

A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease (GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high risk non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma (HL)

NCT ID: NCT01050764 Terminated - Clinical trials for Myelodysplastic Syndrome (MDS)

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Start date: June 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with hematologic malignancies will receive myeloablative chemotherapy followed by stem cell rescue with bone marrow or hematopoietic peripheral blood stem cells collected by apheresis from a filgrastim- (G-CSF)-mobilized haploidentical related-donor, ie, hematopoietic peripheral blood stem cell transplant (HSCT).